Skip to content
Parakho

Thyrocare Technologies Ltd

NSE THYROCAREBSE 539871thyrocare.comInvestor relations

Q1 FY27, unaudited

Revenue
₹240.02 Cr
Profit after tax
₹51.33 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations240.02+24.34%829.04
Other income4.15−10.75%16.99
Total income244.17+23.52%846.03
Employee benefit expense39.61+20.03%138.06
Finance costs1.35+73.08%2.80
Depreciation & amortisation12.49+9.47%58.58
Total expenses176.59+19.76%628.38
Profit before tax67.58+34.54%211.49
Tax expense16.96+39.13%50.03
Profit after tax51.33+34.06%162.85
Total comprehensive income51.72+35.89%163.23
Earnings per share
Earnings per share, basic₹3.23₹10.27
Earnings per share, diluted₹3.22₹10.24

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Earnings call

Q1 FY27

Thyrocare reported consolidated revenue growth of 24.3% and standalone revenue growth of 26.1% in Q1 FY27, with pathology business revenue growing 26% year-on-year. Management highlighted the commercial launch of its Specialty Diagnostics business covering allergy and genomics testing, alongside continued growth in franchisee and partnership channels. The company also discussed a planned divestment of its radiology/nuclear business and updates on franchisee network expansion.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary

Earlier calls: Q4 FY26 · All quarters

Filings

12 shown · 64 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 19 Aug 2026.

Thyrocare Technologies Ltd (THYROCARE) — filings and results · Parakho